

Recent Publications

- ◆ Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. *New England Journal of Medicine*. 2008 Feb(7);358:661-663. [PubMed](#)
- ◆ Freeman RB, Cohen JT. Transplantation risks and the real world: what does 'high risk' really mean? *Am J Transplant* 2009; 9 (1):23-30. [PubMed](#)
- ◆ Meckley LM, Greenberg D, Cohen JT, Neumann PJ. The Adoption of Cost-Effectiveness Acceptability Curves in Cost-Utility Analyses. *Medical Decision Making*. Published online Sept 2009. [PubMed](#)
- ◆ Neumann PJ, Fang CH, Cohen JT. 30 years of pharmaceutical cost-utility analyses: growth, diversity, and methodological improvement. *Pharmacoeconomics* 2009;27(10):861-872. [PubMed](#)
- ◆ Neumann PJ, Greenberg D. Is the U.S. ready for QALYs? *Health Affairs* 2009;28(5):1366-1371. [PubMed](#)
- ◆ Neumann PJ. Costing and perspective in published cost-effectiveness analyses. *Medical Care*. 2009;47(7s1):s28-s32. [PubMed](#)
- ◆ Neumann PJ. Lessons for health technology assessment: It is not only about the evidence. *Value Health* 2009; 12 (s2):s45-s48. [PubMed](#)
- ◆ Neumann PJ. Whatever happened to FDAMA Section 114? A look back after 10 years. *Value Health* 2009; 12(2):189-190. [PubMed](#)
- ◆ Neumann PJ. American exceptionalism and American health care: Implications for the U.S. debate on cost-effectiveness analysis. *Office of Health Economics Briefing*. 2009;47. [Click Here](#)
- ◆ Neumann PJ, Kamae MS, Palmer JA. Medicare's national coverage decisions for technologies, 1999-2007. *Health Affairs* 2008 Nov;27(6):1620-1631. [PubMed](#)
- ◆ Rosen AB, Spaulding A, Greenberg D, Palmer JA, Neumann PJ. Patient adherence: A blind spot in cost-effectiveness analysis? *American Journal of Managed Care* 2009 Sep;15(9):626-32. [PubMed](#)

CEVR in the News

[Boston Globe](#)
[Congressional Budget Office](#)
[Marketwatch](#)
[Minnesota Public Radio](#)
[Omaha World Herald](#)
[Slate.com](#)

From the Director

Welcome to the first edition of the newsletter of the Center for the Evaluation of Value and Risk in Health (CEVR). This e-newsletter is designed to keep you up to date on the work that we are doing and its impact on health and health care.



Peter J. Neumann, ScD

Is the United States Ready for QALYs?"

Our new Health Affairs paper reviews the debate and the use of QALYs in other countries and discusses prospects for using them in the U.S. health care system. Strict adherence to a QALY approach is likely to prove unacceptable in the United States, but a more flexible use of QALYs could be beneficial.

Neumann PJ, Greenberg D. Is the U.S. ready for QALYs? *Health Affairs* 2009;28(5):1366-1371. [PubMed](#)

Prevention and Cost-Effectiveness

In a new report and policy brief for the Robert Wood Johnson Foundation's Synthesis Project, Josh Cohen and Peter Neumann analyze the cost savings and cost-effectiveness of clinical preventive care.

[Download the report here](#)

New Projects

- ◆ An assessment of the opportunities to improve the value obtained from Medicare spending through identification of high-value and low-value services
- ◆ An investigation of how the framing of health benefits affects individuals' preferences for new cancer treatments
- ◆ An examination of value-based payment and coverage policies for Medicare
- ◆ An analysis of individuals' willingness-to-pay for diagnostic technology and how people value diagnostic technologies

CEVR Value Databases

CEVR is the home of the **Cost-Effectiveness Analysis Registry**, a comprehensive, online database of over 1,700 cost-utility analyses on a wide variety of diseases and treatments (www.cearegistry.org). The CEA Registry consists of detailed abstracted information on published cost-effectiveness studies and is regularly updated by a team of researchers. **2008 data will be posted at the end of October**, raising the total number of studies in the database to over 2000.

CEVR's **Tufts Medical Center Medicare National Coverage Decisions (NCDs) Database** captures decisions made by the Centers for Medicare and Medicaid Services (CMS). CMS issues NCDs annually for 10-15 technologies projected to have a major impact on the program. This database contains over 30 variables for 132 NCDs completed between 1999 and 2008, with updates ongoing. The data is used to identify trends in CMS policies and predict factors that most influence Medicare coverage.

Become a Sponsor

We actively seek the support of organizations committed to using clinical and economic evidence to inform health care decisions.

Selected sponsorship benefits:

- ◆ Access to the most updated CEA Registry data and exclusive access to our proprietary Medicare NCD database
- ◆ An invitation to our invitation-only Annual Data and Value Strategy User's Meeting
- ◆ Priority opportunities for *customized* data analyses

If you would like to learn more, visit our [website](#) or contact our Research Manager, [Amy Stern](#) for more information.